The third area for future research entails the discovery of therapies that specifically target the MHC- peptide (autoantigen)-T cell pathway, thus providing a powerful therapeutic approach to induce remission of AILD. Here, HLA-C is linked to angioimmunoblastic T-cell lymphoma.